Full history for every metric is available with a Kvantra account
Elevation Oncology, Inc. (ELEV)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -45 | -49 | |||||
| Net profit | $m | -6 | -17 | -32 | -95 | -46 | -44 | -48 |
| EPS reported | $ | -0.78 | -0.82 | |||||
| Operating cashflow per share | $ | -0.63 | -0.63 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.63 | -0.63 | |||||
| Free cash flow | $m | -36 | -39 | |||||
| Net debt | $m | -62 | -49 | |||||
| Book value equity | $m | 60 | 47 | |||||
| Book value per share | $ | 1.05 | 0.79 | |||||
| Number of shares | m | 57.28 | 59.17 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.54 | 0.46 | |||||
| P/S LTM | x | 0.00 | 569.14 | |||||
| P/FCF LTM | x | -0.89 | -0.55 | |||||
| EV/EBITDA LTM | x | -0.32 | 0.58 | |||||
| EV/Sales LTM | x | 0.00 | -731.02 | |||||
| Earnings Yield LTM | % | -138.05% | -212.79% | |||||
| FCF Yield | % | -112.85% | -182.64% | |||||
| Quality | ||||||||
| ROE | % | -74.11% | -77.48% | |||||
| ROIC | % | -49.04% | -49.04% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -34.48% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.17 | -1.26 | |||||
| Net Debt/EBITDA | x | 0.42 | 0.42 | |||||
| EBIT/Net interest | x | -11.18 | -11.18 | |||||
| Net debt/market cap | % | -192.56% | -228.44% | |||||
| Net debt/Equity | x | -1.03 | -1.06 | |||||
| Gross debt/equity | x | 0.52 | 0.67 | |||||
Company overview
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Elevation Oncology, Inc. (ELEV)
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free